Name | Value |
---|---|
Revenues | 174.0K |
Cost of Revenue | 0.0K |
Gross Profit | 174.0K |
Operating Expense | 3,924.4K |
Operating I/L | -3,750.4K |
Other Income/Expense | -38.7K |
Interest Income | 0.2K |
Pretax | -3,789.1K |
Income Tax Expense | 0.0K |
Net Income/Loss | -3,789.1K |
Lexaria Bioscience Corp. is a biotechnology company specializing in drug delivery technology. Its patented DehydraTECH enhances the oral delivery of active pharmaceutical ingredients, significantly increasing bio-absorption and reducing onset time. The technology is applicable to cannabinoids, nicotine, anti-viral drugs, NSAIDs, PDE5 inhibitors, and more. With 23 patents granted and approximately 50 patents pending globally, the company operates a licensed in-house research laboratory. By licensing its technology and intellectual property, Lexaria Bioscience generates revenue from pharmaceutical and biotech companies seeking to improve the effectiveness of their drug delivery methods.